From bench to bedside: Lessons learned in translating preclinical studies in cancer drug development

Christopher H. Lieu, Aik Choon Tan, Stephen Leong, Jennifer R. Diamond, S. Gail Eckhardt

Research output: Contribution to journalReview articlepeer-review

46 Citations (Scopus)


The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment of numerous cancers. Unfortunately, not all success at the bench in preclinical experiments has translated to success at the bedside. As preclinical studies shift toward defining proof of mechanism, patient selection, and rational drug combinations, it is critical to understand the lessons learned from prior translational studies to gain an understanding of prior drug development successes and failures. By learning from prior drug development, future translational studies will provide more clinically relevant data, and the underlying hope is that the clinical success rate will improve and the treatment of patients with ineffective targeted therapy will be limited.

Original languageEnglish
Pages (from-to)1441-1456
Number of pages16
JournalJournal of the National Cancer Institute
Issue number19
Publication statusPublished - 2013 Oct 2

Bibliographical note

Funding Information:
This work was supported by the National Cancer Institute K12 (5K12CA132783-03) Paul Calabresi Career Development Award for Clinical Oncology.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'From bench to bedside: Lessons learned in translating preclinical studies in cancer drug development'. Together they form a unique fingerprint.

Cite this